贫血预测铁稳态失调并调节射血分数降低心衰患者对恩格列净的反应:EMPATROPISM-FE 试验
该研究为 EMPATROPISM-FE 试验的事后分析,在 80 例射血分数降低心衰患者中评估基线贫血状态与铁稳态、心脏结构功能、运动能力、造血及交感活性的关系,并比较恩格列净与安慰剂治疗 6 个月的效果。结果显示贫血患者心肌铁含量更低、运动能力更差且交感活性更高,恩格列净可增加心肌铁含量、改善运动能力并激活造血,贫血患者左室逆重构更显著。
要点
- 贫血心衰患者心肌铁含量更低、运动能力更差、交感活性更高。
- 恩格列净增加心肌铁含量、改善运动能力并激活造血。
- 贫血患者接受恩格列净后左室逆重构更显著。
核心结论
- 细胞铁摄取/可利用性失调可能是心衰心肌结构功能受损、运动能力下降和造血受限的共同机制,贫血患者更严重且恩格列净可改善。
- 恩格列净增加心肌铁含量并降低去甲肾上腺素,交感溶解可能解释 SGLT2i 的多重心血管获益。
研究设计与样本
- EMPATROPISM-FE 研究的事后分析,比较恩格列净与安慰剂治疗 6 个月。
- 共纳入 80 例射血分数降低心衰患者,基线及 6 个月评估心肌铁含量、左室容积与射血分数、运动能力、铁标志物、血红蛋白/红细胞压积、促红细胞生成素及血浆去甲肾上腺素。
主要发现
- 基线时 24/80 例(30%)存在贫血(血红蛋白男性<13 mg/dL、女性<12 mg/dL)。
- 贫血患者较无贫血者 T2* 更高(提示心肌铁含量更低,P<.001)、峰值耗氧量更低(P=.024)、铁调素更低(P=.017)、促红细胞生成素更高(P=.040)及去甲肾上腺素更高(P=.016)。
- 心肌铁含量越低与左室容积越大(P<.01)、去甲肾上腺素越高(P<.001)、左室射血分数越低(P<.01)、峰值耗氧量越低(P<.001)及血红蛋白/红细胞压积越低(P<.001)相关,与实验室铁标志物关联差(均 P>.10)。
- 恩格列净增加心肌铁含量(P<.012)、改善运动能力并激活造血;铁标志物和去甲肾上腺素变化提示进行性系统性铁耗竭和交感溶解;贫血患者左室逆重构更显著。
临床怎么用
- 在心衰患者中应关注贫血状态,其与更差的心肌铁含量、运动能力和交感激活相关。
- 恩格列净治疗可能通过增加心肌铁含量和交感溶解带来心脏及全身获益,贫血患者左室逆重构可能更明显。
局限性
- 为事后分析,样本量 80 例,结果需在更大规模研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) impact iron metabolism in patients with heart failure but mechanisms are incompletely understood. This post hoc analysis explored interrelations between iron homeostasis, cardiac structure/function, exercise capacity, haematopoiesis, and sympathetic activity at baseline, and the effects of 6-month treatment with empagliflozin vs. placebo by anaemia status in EMPATROPISM-FE study participants. METHODS: Myocardial iron content (MIC, estimated by cardiac magnetic resonance T2* imaging), left ventricular (LV) volumes and LV ejection fraction (LVEF), exercise capacity, laboratory iron markers (LIM), haemoglobin/haematocrit, erythropoietin, and plasma norepinephrine were determined at baseline and 6 months. RESULTS: At baseline, 24/80 participants (30%) had anaemia (haemoglobin < 13/<12 mg/dL in men/women). Patients with vs. without anaemia had higher T2* (indicating lower MIC, P < .001), lower peak oxygen consumption (VO2max, P = .024) and hepcidin (P = .017), and higher erythropoietin (P = .040) and norepinephrine (P = .016). Across subgroups, lower MIC correlated with higher LV volumes (P < .01) and norepinephrine (P < .001), and lower LVEF (P < .01), VO2max (P < .001) and haemoglobin/haematocrit (P < .001). Associations with LIM were poor (all P > .10). Empagliflozin increased MIC (P < .012), improved exercise capacity, and activated haematopoiesis. Changes in LIM and norepinephrine suggested progressive systemic iron depletion and sympatholysis. LV reverse remodelling was greater in individuals with anaemia. CONCLUSIONS: Dysregulated cellular iron uptake/availability may be a shared mechanism in myocardial structural/functional impairment, reduced exercise capacity, and restricted haematopoiesis in heart failure, which are worse in patients with anaemia, and improve with empagliflozin. Empagliflozin increases MIC and decreases norepinephrine. Given this inverse association, sympatholysis may help explain the diverse cardiac and systemic benefits from SGLT2i therapy. CLINICAL TRIAL REGISTRATION: NCT03485222 (www.clinicaltrials.gov).
引用
- Angermann, Sehner, Gerhardt, et al. Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial. Eur Heart J. 2025. PMID: 39907687. doi:10.1093/eurheartj/ehae917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。